优化 - 突变型黑色素瘤的靶向治疗机会。
Refining Targeted Therapy Opportunities for -Mutant Melanoma.
机构信息
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Division of Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
出版信息
Cancer Discov. 2017 Aug;7(8):799-801. doi: 10.1158/2159-8290.CD-17-0607.
Identifying molecular and cellular features associated with resistance to targeted BRAF/MAPK pathway inhibition may guide development of novel therapeutic approaches. Integrated, comparative analysis of genomic and functional data in sensitive and resistant cell lines unveils novel targetable regulators of resistance to MAPK pathway inhibition in melanoma. .
鉴定与针对 BRAF/MAPK 通路抑制的耐药性相关的分子和细胞特征，可能有助于指导新的治疗方法的开发。在敏感和耐药细胞系中对基因组和功能数据进行综合比较分析，揭示了黑色素瘤中针对 MAPK 通路抑制耐药性的新型可靶向调控因子。
Zotero 插件